Does Wegovy work long term — and what does the evidence actually say?

The biggest misconception: that Wegovy stops working over time

A common worry is that the body adapts and the medicine loses its effect the longer you take it. The trial data tell a different story. In the STEP 1 study published in the New England Journal of Medicine, weight loss continued to progress through the escalation phase and then stabilised at the higher maintenance doses, it didn't plateau and reverse while treatment was active. What people often confuse with the medicine "stopping working" is the natural levelling-off that happens once the body reaches a new equilibrium. That isn't failure; it's how appetite regulation works in response to sustained lower energy intake and slower gastric emptying. The medicine continues to do its job; the body has simply found a new set point. So if the question is whether Wegovy keeps suppressing appetite and supporting weight management month after month while you take it, the evidence says yes. The more complicated question is what happens when treatment ends.

For anyone curious about the purpose Wegovy is actually licensed for, it's worth knowing the UK indication covers weight management alongside a reduced-calorie diet and increased activity, not as a standalone fix, but as part of a wider approach.

What happens to weight when Wegovy is stopped

This is the part that surprises people. The STEP 4 withdrawal trial is instructive: participants who stopped semaglutide after 20 weeks of treatment regained approximately two-thirds of their lost weight within a year. That finding matters because it reframes the question. Wegovy isn't a course of antibiotics you complete and then move on from, for many people, it is more like a treatment for an ongoing condition. Obesity is shaped by biology, hormones and appetite signalling that reassert themselves when the medicine is withdrawn. Stopping isn't a failure; it's a physiological response.

This is why the question of whether you can stay on Wegovy long term is one worth discussing openly with a prescriber rather than assuming either way. Some people will reach a point where lifestyle changes have taken root firmly enough to maintain weight without the medicine; others will find that the biology pulls back strongly. Neither outcome says anything about willpower.

NICE's recommendation for semaglutide on the NHS caps use at two years within a specialist service. That ceiling doesn't apply in the same way to private prescribing, where a prescriber reviews suitability at each repeat, but it's a useful marker of how UK clinicians think about treatment duration.

Side effects over an extended course, what's known

The NHS medicines page for semaglutide is the clearest starting point. Gastrointestinal effects (nausea, loose stools, constipation, reflux) are most noticeable early in treatment and after dose increases, and for most people they ease significantly within a few weeks of settling on a stable dose. Over a longer course, those acute GI effects tend to become a background feature rather than a daily disruption.

Longer-term safety monitoring continues via the MHRA's Black Triangle (▼) scheme, which applies to Wegovy because it's a relatively recently authorised medicine. That designation exists precisely to capture any signals that emerge with wider real-world use over time. If you notice anything unexpected at any point, the Yellow Card scheme at yellowcard.mhra.gov.uk is how patients report suspected side effects directly to the regulator. The long-term effects of Wegovy remain an active area of post-marketing surveillance, and the honest answer is that the multi-year dataset will keep building for several more years yet.

One note on timing: if you're thinking about starting treatment and wondering whether to wait until payday, or until after a holiday, there's rarely a perfect window, the clinical review process is the same regardless of when you apply, and any week you start is a week ahead.

How long-term Wegovy use is managed in practice

For people using Wegovy privately through a regulated pharmacy, the process doesn't change once you've been on treatment for a while. A prescriber reviews your case before every repeat order, checking that the medicine is still appropriate, that your weight progress makes clinical sense, and that there are no new reasons to reconsider. There is no auto-renewal.

If you're exploring what Wegovy long-term use looks like in practice, including dose management and what ongoing clinical support covers, that's a reasonable thing to read through before your consultation. Cost is a real consideration for treatment that may run for years; our guide to Wegovy pricing in the UK covers what private treatment typically costs and what to look for in a legitimate provider.

At nume, a GPhC-registered prescriber personally reviews every consultation and every repeat, not a checklist algorithm. Our pharmacy holds GPhC premises registration 9012878, verifiable directly on the GPhC register. If you're ready to talk through whether Wegovy is a suitable long-term option for you, speak to our prescribers through a free consultation.